These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 22677045)

  • 21. Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis.
    Blauvelt A
    Expert Opin Biol Ther; 2016; 16(2):255-63. PubMed ID: 26666707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
    Reich K; Papp KA; Matheson RT; Tu JH; Bissonnette R; Bourcier M; Gratton D; Kunynetz RA; Poulin Y; Rosoph LA; Stingl G; Bauer WM; Salter JM; Falk TM; Blödorn-Schlicht NA; Hueber W; Sommer U; Schumacher MM; Peters T; Kriehuber E; Lee DM; Wieczorek GA; Kolbinger F; Bleul CC
    Exp Dermatol; 2015 Jul; 24(7):529-35. PubMed ID: 25828362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
    Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
    Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GILZ regulates Th17 responses and restrains IL-17-mediated skin inflammation.
    Jones SA; Perera DN; Fan H; Russ BE; Harris J; Morand EF
    J Autoimmun; 2015 Jul; 61():73-80. PubMed ID: 26077873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting IL-17 with ixekizumab in patients with psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Immunotherapy; 2015; 7(9):957-66. PubMed ID: 26569072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients.
    Cao H; Su S; Yang Q; Le Y; Chen L; Hu M; Guo X; Zheng J; Li X; Yu Y
    Lipids Health Dis; 2021 Feb; 20(1):16. PubMed ID: 33602246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
    Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
    J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psoriasis: rationale for targeting interleukin-17.
    Girolomoni G; Mrowietz U; Paul C
    Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
    Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
    Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model.
    Chen W; Gong Y; Zhang X; Tong Y; Wang X; Fei C; Xu H; Yu Q; Wang Y; Shi Y
    J Dermatol Sci; 2017 Feb; 85(2):115-123. PubMed ID: 27939414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
    Page KM; Suarez-Farinas M; Suprun M; Zhang W; Garcet S; Fuentes-Duculan J; Li X; Scaramozza M; Kieras E; Banfield C; Clark JD; Fensome A; Krueger JG; Peeva E
    J Invest Dermatol; 2020 Aug; 140(8):1546-1555.e4. PubMed ID: 31972249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
    Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
    Front Immunol; 2020; 11():1894. PubMed ID: 32973785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
    Krueger JG; Ferris LK; Menter A; Wagner F; White A; Visvanathan S; Lalovic B; Aslanyan S; Wang EE; Hall D; Solinger A; Padula S; Scholl P
    J Allergy Clin Immunol; 2015 Jul; 136(1):116-124.e7. PubMed ID: 25769911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.
    Brembilla NC; Senra L; Boehncke WH
    Front Immunol; 2018; 9():1682. PubMed ID: 30127781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
    Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psoriasis and other Th17-mediated skin diseases.
    Tokura Y; Mori T; Hino R
    J UOEH; 2010 Dec; 32(4):317-28. PubMed ID: 21226422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and early clinical data on IL-17 blockade in psoriasis.
    Nwe SM; Champlain AH; Gordon KB
    Expert Rev Clin Immunol; 2013 Jul; 9(7):677-82. PubMed ID: 23899238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
    Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
    Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.
    Ma L; Xue H; Qi R; Wang Y; Yuan L
    J Transl Med; 2018 Mar; 16(1):59. PubMed ID: 29523162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.